James Mckay

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the…

Arthritis & Rheumatism · 2008 · 657 citations

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

Arthritis & Rheumatism · 2009 · 430 citations